Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 14/20 | 0.52 |
| ▸ | METTL3 | Q86U44 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | TTR | P02766 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | FABP2 | P12104 | 1/20 | 0.52 |
| ▸ | RXRA | P19793 | 1/20 | 0.52 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.52 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.52 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.52 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.52 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30794951 | 1.00 | PTGS2 (0.52) | PTGS2METTL3MEN1MAPK1KMT2A | |
| SCHEMBL449648 | 0.89 | PTGS2 (0.49) | PTGS2METTL3MEN1MAPK1KMT2A | |
| SCHEMBL30795150 | 0.89 | PTGS2 (0.49) | PTGS2METTL3MEN1MAPK1KMT2A | |
| SCHEMBL451381 | 0.85 | CXCL8 (0.49) | PTGS2MEN1MAPK1KMT2AAKR1B10 | |
| SCHEMBL30794423 | 0.80 | GSTO1 (0.44) | PTGS2FTOCXCL8CYP1A2CYP3A4 | |
| SCHEMBL439442 | 0.80 | GSTO1 (0.44) | PTGS2FTOCXCL8CYP1A2CYP3A4 | |
| SCHEMBL449207 | 0.76 | MCL1 (0.43) | CXCL8LMNACYP1A2CYP3A4GAA | |
| SCHEMBL30794636 | 0.76 | MCL1 (0.43) | CXCL8LMNACYP1A2CYP3A4GAA | |
| SCHEMBL9307678 | 0.73 | ALDH1A1 (0.56) | MEN1MAPK1KMT2AUSP2LMNA | |
| SCHEMBL13189148 | 0.73 | GSTO1 (0.55) | MEN1MAPK1KMT2AGMNNLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466201-B2 | Potassium ion channel modulators and uses thereof | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2013-06-18 | — | — | US | claimed |
| EP-2231594-B1 | POTASSIUM ION CHANNEL MODULATORS AND USES THEREOF | UNIV RAMOT (IL) | 2013-03-27 | — | — | EP | claimed |
| US-20120065270-A1 | POTASSIUM ION CHANNEL MODULATORS AND USES THEREOF | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2012-03-15 | — | — | US | claimed |
| EP-2231594-A2 | POTASSIUM ION CHANNEL MODULATORS AND USES THEREOF | Ramot at Tel-Aviv University Ltd (IL) | 2010-09-29 | — | — | EP | claimed |
| WO-2009071947-A2 | POTASSIUM ION CHANNEL MODULATORS & USES THEREOF | LECTUS THERAPEUTICS LIMITED (GB) | 2009-06-11 | — | — | WO | claimed |
| US-8466201-B2 | Potassium ion channel modulators and uses thereof | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2013-06-18 | — | — | US | disclosed |
| EP-2231594-B1 | POTASSIUM ION CHANNEL MODULATORS AND USES THEREOF | UNIV RAMOT (IL) | 2013-03-27 | — | — | EP | disclosed |
| US-20120065270-A1 | POTASSIUM ION CHANNEL MODULATORS AND USES THEREOF | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2012-03-15 | — | — | US | disclosed |
| EP-2231594-A2 | POTASSIUM ION CHANNEL MODULATORS AND USES THEREOF | Ramot at Tel-Aviv University Ltd (IL) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009071947-A2 | POTASSIUM ION CHANNEL MODULATORS & USES THEREOF | LECTUS THERAPEUTICS LIMITED (GB) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065270-A1 | POTASSIUM ION CHANNEL MODULATORS AND USES THEREOF | KCNN3, SCN2B, SCN1B | PTGS2 1885/4885METTL3 1646/4885MEN1 3291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.